Notice: This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture FinancingMay 29, 2023 | finance.yahoo.comITeos Therapeutics Inc Ordinary SharesMay 27, 2023 | morningstar.comENDV Endonovo Therapeutics, Inc.May 20, 2023 | seekingalpha.comLooking Into Oncternal Therapeutics's Return On Capital EmployedMay 18, 2023 | msn.comAnticompetitive Behavior At United Therapeutics, Regeneron, And The FTCMay 18, 2023 | msn.comFTC sues to block Amgen’s acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comFTC sues to block Amgen acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comRecap: Abeona Therapeutics Q1 EarningsMay 12, 2023 | msn.comTScan Therapeutics More than Doubles Following Deal with AmgenMay 9, 2023 | msn.comMersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual MeetingApril 26, 2023 | benzinga.comPerspective Therapeutics, Inc.: Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of BrachytherapyApril 5, 2023 | finanznachrichten.deCigna's PBM, two others sued in Ohio over drug price fixing - WSJMarch 27, 2023 | news.yahoo.comDefence Therapeutics Inc.: Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine PlatformFebruary 25, 2023 | finanznachrichten.deVoyager Therapeutics Stock (NASDAQ:VYGR), Quotes and News SummaryFebruary 18, 2023 | benzinga.comMolina Healthcare, Inc. (NYSE:MOH) Q4 2022 Earnings Call TranscriptFebruary 11, 2023 | yahoo.comRevance Therapeutics Stock (NASDAQ:RVNC), Quotes and News SummaryFebruary 10, 2023 | benzinga.comJnana Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2023 | markets.businessinsider.comDown -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a TurnaroundDecember 29, 2022 | msn.comOnconova Therapeutics's Return On Capital Employed InsightsDecember 27, 2022 | benzinga.com3 Reasons Amgen Is Buying Horizon — and Why It Wasn’t the Only Company InterestedDecember 13, 2022 | barrons.comAmgen to buy Horizon Therapeutics in $26.4 billion dealDecember 13, 2022 | msn.comHere's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022December 12, 2022 | msn.comRule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plcDecember 12, 2022 | markets.businessinsider.comAmgen secures $28.3 billion deal to buy Horizon TherapeuticsDecember 12, 2022 | msn.comAmgen to Buy Horizon Therapeutics in $27.8 Billion DealDecember 12, 2022 | msn.comAmgen Is Said to Agree to Buy Horizon at $26 Billion ValuationDecember 12, 2022 | msn.comEndonovo Names Ira Weisberg President to Guide Global Medical ExpansionNovember 30, 2022 | yahoo.comRoche In Drug Discovery Deal With Jnana TherapeuticsNovember 15, 2022 | markets.businessinsider.comAnthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, AbelacimabAugust 26, 2022 | finance.yahoo.comGlobal Gene Therapy Market Analysis Report 2022-2026: Adeno-associated Virus Vectors - A Leading Platform for Gene TherapyAugust 24, 2022 | benzinga.comAlaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy ConferenceAugust 24, 2022 | finance.yahoo.com Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address ANCN Media Mentions By Week ANCN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANCN News Sentiment▼0.000.60▲Average Medical News Sentiment ANCN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANCN Articles This Week▼00▲ANCN Articles Average Week Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GBIO News ONCY News IMRX News FBLG News GANX News KRON News HOWL News RVPH News ELYM News PRLD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANCN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
